<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="1381">
  <stage>Registered</stage>
  <submitdate>24/11/2006</submitdate>
  <approvaldate>24/11/2006</approvaldate>
  <nctid>NCT00403897</nctid>
  <trial_identification>
    <studytitle>An Open Single Centre Study To Assess Treatment of Chronic Constipation in Children</studytitle>
    <scientifictitle>An Open Single Centre Study To Assess the Safety and Efficacy of Movicol in the Treatment of Chronic Constipation in Children</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>99/04</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Chronic Constipation</healthcondition>
    <conditioncode>
      <conditioncode1>Oral and Gastrointestinal</conditioncode1>
      <conditioncode2>Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Polyethylene glycol 3350 Na bicarbonate NaCl KCl

Experimental: 1 - Ages 2 - 6: Day 1= 1 sachet/day; Day 3= 1 sachet BID; Day 5= 1 sachet TID Ages 7 - 11: Day 1= 1 sachet BID; Days 3 &amp; 5 = 2 sachets BID;


Treatment: drugs: Polyethylene glycol 3350 Na bicarbonate NaCl KCl
6.9g sachet, oral

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>The average number of spontaneous complete defaecations per week recorded over the period of treatment between scheduled visits.</outcome>
      <timepoint />
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Assessment of</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>abdominal pain</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>amount of stool</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>faecal form (Bristol stool scale)</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>rectal bleeding</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>pain on defaecation</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>straining on defaecation</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>stool withholding</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>faecal incontinence (soiling)</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>efficacy (investigator and parental assessment)</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>concomitant laxative treatment</outcome>
      <timepoint />
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  children aged 24 months - 11 years old inclusive

          -  patients with constipation defined as:

               -  = 2 spontaneous complete bowel movements per week (over the previous 14 days),
                  and one or more of the following:

                    -  1/4 or more of bowel movements with straining

                    -  1/4 or more of bowel movements with hard or lumpy stools

          -  patients in whom these symptoms have been present for = 3 months

          -  new patients or those whose management is unsatisfactory on current laxative treatment

          -  patients of either sex

          -  patients of any ethnic origin

          -  hospital in-patients or outpatients.</inclusivecriteria>
    <inclusiveminage>24</inclusiveminage>
    <inclusiveminagetype>Months</inclusiveminagetype>
    <inclusivemaxage>11</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Patients with:

          -  history of bowel washout within the last 2 months

          -  intestinal perforation or history of obstruction

          -  recent history of urinary tract infection (within last month)

          -  Hirschsprungs disease

          -  paralytic ileus

          -  toxic megacolon

          -  severe inflammatory conditions of the intestinal tract

          -  clinically uncontrolled renal/hepatic/cardiac disease(s)

          -  clinically uncontrolled endocrine disorder(s)

          -  any other severe unstable co-existing disease

          -  hypersensitivity to macrogol or other constituents of Movicol

          -  encopresis

          -  patients who have taken any investigational drug in the last three months

          -  patients or patients whose parents would in the opinion of the investigator be unable
             to comply with the requirements of the study.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/08/2001</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>81</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
    <hospital>Royal Children's Hospital - Parkville</hospital>
    <postcode>3052 - Parkville</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Norgine</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study was to evaluate the safety and efficacy of Movicol in the treatment
      of chronic constipation in children.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00403897</trialwebsite>
    <publication>Attar A, Lémann M, Ferguson A, Halphen M, Boutron MC, Flourié B, Alix E, Salmeron M, Guillemot F, Chaussade S, Ménard AM, Moreau J, Naudin G, Barthet M. Comparison of a low dose polyethylene glycol electrolyte solution with lactulose for treatment of chronic constipation. Gut. 1999 Feb;44(2):226-30.
</publication>
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Winita Hardikar, MD</name>
      <address>Royal Children's Hospital</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>